Non challengers | Challengers | p-value |
Passive challengers | Aggressive challengers | p-value | |
---|---|---|---|---|---|---|
94 | 77 | 58 | 19 | |||
Innovative | ||||||
No | 85 | 57 | 0.0083 | 46 | 11 | 0.1221 |
Yes | 9 | 20 | 12 | 8 | ||
New drug | ||||||
No | 85 | 44 | < 0.0001 | 36 | 8 | 0.2080 |
Yes | 9 | 33 | 22 | 11 | ||
Sales |
87,321 (175,878) |
213,598 (271,251) | 0.0005 |
183,181 (263,621) |
306,449 (280,190) | 0.0856 |
Employees |
239 (339) |
515 (510) | < 0.0001 |
433 (436) |
765 (637) | 0.0448 |
Reimbursed drugs |
73 (76.7) |
189 (69.4) | < 0.0001 |
170 (56.9) |
248 (72.3) | < 0.0001 |